Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 3;7(2):rkad035.
doi: 10.1093/rap/rkad035. eCollection 2023.

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study

Magnus B Petersen  1 , Rebekka L Hansen  1 , Alexander Egeberg  2 , Tanja S Jørgensen  1   3 , Joseph Frank Merola  4 , Laura C Coates  5 , Lars Erik Kristensen  1
Affiliations

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study

Magnus B Petersen et al. Rheumatol Adv Pract. .

Abstract

Objective: To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.

Methods: Patients were divided into three groups depending on the presence and/or severity of comorbidities using the Charlson Comorbidity Index (CCI). Groups were CCI 0: no comorbidities, CCI 1: one comorbidity and CCI ≥2: two or more comorbidities or one or more severe comorbidities. Outcomes in the groups were compared for treatment persistence, treatment response and disease activity.

Results: A higher CCI score was associated to an elevation in baseline CRP, swollen joint count and frequency of depression and/or anxiety. The median drug persistence in the groups were CCI 0: 1.8 years, CCI 1: 1.9 years and CCI ≥2: 1.5 years, but was not statistically significant to the CCI score. There were no significant differences in clinical response rates between the groups.

Conclusion: The presence of comorbidities was associated with increased baseline disease activity and frequency of depression and/or anxiety, but was not associated with shorter treatment persistence or lower clinical response rates in a cohort of 155 Danish patients with PsA treated with first-line IL-17i.

Keywords: IL-17 inhibitor; PsA; comorbidities; disease activity; treatment persistence; treatment response.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier plot of IL-17i persistence in patients with CCI scores of 0, 1 or ≥2
See this image and copyright information in PMC

References

    1. Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D.. An overview of psoriatic arthritis – epidemiology, clinical features, pathophysiology and novel treatment targets. Wien Klin Wochenschr 2016;128:791–5. - PMC - PubMed
    1. Kristensen LE, Jørgensen TS, Christensen R. et al. Societal costs and patients’ experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis 2017;76:1495–501. - PubMed
    1. Mathew AJ, Chandran V.. Depression in psoriatic arthritis: dimensional aspects and link with systemic inflammation. Rheumatol Ther 2020;7:287–300. - PMC - PubMed
    1. Ogdie A, Schwartzman S, Husni ME.. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015;27:118–26. - PubMed
    1. Gossec L, Baraliakos X, Kerschbaumer A. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700–12. - PMC - PubMed

LinkOut - more resources